Last reviewed 2026-04-22 · How we verify

Iguratimod Tablets

Iguratimod is a small-molecule immunomodulator that suppresses inflammatory cytokine production and modulates immune cell function to reduce inflammation.

Iguratimod is a small-molecule immunomodulator that suppresses inflammatory cytokine production and modulates immune cell function to reduce inflammation. Used for Rheumatoid arthritis.

At a glance

Mechanism of action

Iguratimod inhibits the production of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-8, while also promoting the differentiation of regulatory T cells. It acts through multiple pathways including NF-κB signaling inhibition and has been shown to reduce synovial inflammation and joint damage in rheumatoid arthritis models.

Approved indications

• Rheumatoid arthritis

Common side effects

• Gastrointestinal disturbances
• Elevated liver enzymes
• Infection

Key clinical trials

• Clinical Trial of Huoluo Pills Combined With Iguratimod Tablets in the Treatment of Rheumatoid Arthritis (NA)
• The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome (PHASE4)
• Efficacy Study of Iguratimod Combined With Tofacitab in Patients With RF Positive/Negative Rheumatoid Arthritis (PHASE4)
• The Efficacy and Safety of Tofacitinib (TF) With Iguratimod (IGU) on RA (PHASE4)
• The Clinical Efficacy and Safety of Iguratimod in RA and Early RA Patients for 6 Months Treatment (PHASE4)
• The Clinical Efficacy of Immunomodulators in RA Patients (PHASE4)
• Efficacy and Safety of Iguratimod in Patients With Hand Osteoarthritis (ESIGO) (PHASE2, PHASE3)
• A Study of Iguratimod in Patients With Active Rheumatoid Arthritis (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.